Pancreatic Cancer Trial, Recruiting NCT07034339 Sponsor: First Affiliated Hospital of Zhejiang University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT07034339
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Healthy people who do not have any known liver, gallbladder, or pancreas conditions (whether cancerous or non-cancerous)
  • People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) for the first time
  • People who have a non-cancerous (benign) tumor of the pancreas
  • People who have been diagnosed with a condition called IPMN (a type of growth in the pancreas) confirmed by medical imaging or tissue testing

Who may not be able to join:

  • People who have an autoimmune disease (a condition where the immune system attacks the body)
  • People who have been diagnosed with any other type of cancer in addition to a pancreatic condition
  • People who have previously received treatment for a tumor (unless it was thyroid or breast cancer that was fully treated more than 5 years ago)
  • People who currently have an active infection
  • People who have had a blood transfusion in the last 6 months, or have taken certain medications that affect blood cells (such as erythropoietin or interleukin) within the last 2 weeks
  • People whose organs (such as the liver, kidneys, or heart) are not functioning properly (confirm with trial site)
  • People who have an immune deficiency condition (such as HIV/AIDS)
  • People who have a pre-cancerous blood condition (confirm with trial site)
  • People who are currently taking medication that suppresses the immune system
  • People who have a diagnosed blood clotting disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13957830918

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
First Affiliated Hospital of Zhejiang University
Registry
ClinicalTrials.gov
Start date
21 May 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pancreatic tumor resection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov